• Je něco špatně v tomto záznamu ?

Coagulation in familial hypercholesterolemic patients: effect of current hypolipidemic treatment and anticoagulants

J. Fadraersada, R. Alva-Gallegos, P. Skořepa, F. Musil, K. Mrštná, L. Javorská, K. Matoušová, LK. Krčmová, M. Paclíková, A. Carazo, M. Bláha, V. Blaha, P. Mladěnka

. 2025 ; 398 (6) : 7343-7352. [pub] 20250103

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015576

Grantová podpora
UHHK, 00179906 MH CZ - DRO
NU21J-02-00021 Czech Health Research Council
SVV 260 549 Charles University

Familial hypercholesterolemia (FH) is a relatively rare genetic disease associated with high serum cholesterol levels but also with abnormalities in blood coagulation. Novel pharmacotherapeutic approaches in FH including proprotein convertase subtilisin/kexin type 9 antibodies (PCSK9Ab) are very efficient in decreasing cholesterol levels but their impact on coagulation in FH is not yet established. Therefore, we hypothesized that these novel antidyslipidemic drugs can positively impact blood coagulation due to their more potent effect on cholesterol. A total of 15 healthy volunteers and all 15 available patients with severe FH treated at the University Hospital Hradec Králové were enrolled, coagulation was assessed by mechanic coagulometer, and the impact of four clinically used direct anticoagulants was analyzed ex vivo. FH patients were treated effectively as their total cholesterol was 4.11 ± 1.57 mM and LDL cholesterol was 2.44 ± 1.46 mM, which were even lower values than detected in our generally healthy controls. Twelve from the 15 FH patients were finally analyzed as 3 were treated with anticoagulants. Coagulation in FH patients was prolonged more extensively by dabigatran and rivaroxaban, when compared to healthy controls. Treatment with PCSK9Ab or lipid apheresis did not seem to have a significant effect on coagulation. The latter procedure however significantly decreased serum levels of one vitamin K form, MK4. Shorter coagulation time was associated with higher levels of LDL, non-HDL, and total cholesterol. Current treatment of FH seems to improve the effects of direct anticoagulants beyond known effects on LDL cholesterol levels.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015576
003      
CZ-PrNML
005      
20250731091106.0
007      
ta
008      
250708s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00210-024-03740-1 $2 doi
035    __
$a (PubMed)39751820
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Fadraersada, Jaka $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
245    10
$a Coagulation in familial hypercholesterolemic patients: effect of current hypolipidemic treatment and anticoagulants / $c J. Fadraersada, R. Alva-Gallegos, P. Skořepa, F. Musil, K. Mrštná, L. Javorská, K. Matoušová, LK. Krčmová, M. Paclíková, A. Carazo, M. Bláha, V. Blaha, P. Mladěnka
520    9_
$a Familial hypercholesterolemia (FH) is a relatively rare genetic disease associated with high serum cholesterol levels but also with abnormalities in blood coagulation. Novel pharmacotherapeutic approaches in FH including proprotein convertase subtilisin/kexin type 9 antibodies (PCSK9Ab) are very efficient in decreasing cholesterol levels but their impact on coagulation in FH is not yet established. Therefore, we hypothesized that these novel antidyslipidemic drugs can positively impact blood coagulation due to their more potent effect on cholesterol. A total of 15 healthy volunteers and all 15 available patients with severe FH treated at the University Hospital Hradec Králové were enrolled, coagulation was assessed by mechanic coagulometer, and the impact of four clinically used direct anticoagulants was analyzed ex vivo. FH patients were treated effectively as their total cholesterol was 4.11 ± 1.57 mM and LDL cholesterol was 2.44 ± 1.46 mM, which were even lower values than detected in our generally healthy controls. Twelve from the 15 FH patients were finally analyzed as 3 were treated with anticoagulants. Coagulation in FH patients was prolonged more extensively by dabigatran and rivaroxaban, when compared to healthy controls. Treatment with PCSK9Ab or lipid apheresis did not seem to have a significant effect on coagulation. The latter procedure however significantly decreased serum levels of one vitamin K form, MK4. Shorter coagulation time was associated with higher levels of LDL, non-HDL, and total cholesterol. Current treatment of FH seems to improve the effects of direct anticoagulants beyond known effects on LDL cholesterol levels.
650    _2
$a lidé $7 D006801
650    12
$a hyperlipoproteinemie typ II $x krev $x farmakoterapie $7 D006938
650    _2
$a mužské pohlaví $7 D008297
650    12
$a hemokoagulace $x účinky léků $7 D001777
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dospělí $7 D000328
650    12
$a antikoagulancia $x terapeutické užití $x farmakologie $7 D000925
650    _2
$a lidé středního věku $7 D008875
650    12
$a hypolipidemika $x terapeutické užití $x farmakologie $7 D000960
650    _2
$a LDL-cholesterol $x krev $7 D008078
650    _2
$a dabigatran $x terapeutické užití $x farmakologie $7 D000069604
650    _2
$a rivaroxaban $x terapeutické užití $x farmakologie $7 D000069552
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a PCSK9 inhibitory $7 D000091362
650    _2
$a anticholesteremika $x terapeutické užití $7 D000924
650    _2
$a cholesterol $x krev $7 D002784
650    _2
$a proproteinkonvertasa subtilisin/kexin typu 9 $7 D000071449
655    _2
$a časopisecké články $7 D016428
700    1_
$a Alva-Gallegos, Raúl $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
700    1_
$a Skořepa, Pavel $u 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic $u Department of Military Internal Medicine and Military Hygiene, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
700    1_
$a Musil, František $u Department of Occupational Medicine, Faculty of Medicine in Hradec Králové, University Hospital, Charles University, Hradec Králové, Czech Republic
700    1_
$a Mrštná, Kristýna $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
700    1_
$a Javorská, Lenka $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Matoušová, Kateřina $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Krčmová, Lenka Kujovská $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
700    1_
$a Paclíková, Markéta $u 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
700    1_
$a Carazo, Alejandro $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic. carazofa@faf.cuni.cz
700    1_
$a Bláha, Milan $u 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
700    1_
$a Blaha, Vladimír $u 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
700    1_
$a Mladěnka, Přemysl $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
773    0_
$w MED00003462 $t Naunyn-Schmiedeberg's archives of pharmacology $x 1432-1912 $g Roč. 398, č. 6 (2025), s. 7343-7352
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39751820 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091100 $b ABA008
999    __
$a ok $b bmc $g 2366432 $s 1252701
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 398 $c 6 $d 7343-7352 $e 20250103 $i 1432-1912 $m Naunyn-Schmiedeberg's archives of pharmacology $n Naunyn Schmiedebergs Arch Pharmacol $x MED00003462
GRA    __
$a UHHK, 00179906 $p MH CZ - DRO
GRA    __
$a NU21J-02-00021 $p Czech Health Research Council
GRA    __
$a SVV 260 549 $p Charles University
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...